<![CDATA[HIStalk Sponsor Announcements - Announcements]]> https://histalk.com/forum/ Thu, 12 Mar 2026 05:08:47 +0000 MyBB <![CDATA[Bizmatics Is Proud to Represent at the ASIPP Annual Meeting]]> https://histalk.com/forum/showthread.php?tid=2277 Tue, 10 Mar 2026 19:08:03 +0000 Jasmine Torres]]> https://histalk.com/forum/showthread.php?tid=2277 ASIPP Annual Meeting from March 19–21, 2026, in New Orleans!

We look forward to connecting with pain management professionals, industry leaders, and healthcare innovators as we showcase the latest advancements in PrognoCIS EHR, including our new AI‑powered capabilities designed to enhance clinical efficiency and support better patient outcomes. 

Attending ASIPP? Connect with Us Today


[Image: ASIPP.png]]]> ASIPP Annual Meeting from March 19–21, 2026, in New Orleans!

We look forward to connecting with pain management professionals, industry leaders, and healthcare innovators as we showcase the latest advancements in PrognoCIS EHR, including our new AI‑powered capabilities designed to enhance clinical efficiency and support better patient outcomes. 

Attending ASIPP? Connect with Us Today


[Image: ASIPP.png]]]> <![CDATA[MEDITECH showcases native ambient intelligence for physcians and nurses at HIMSS26]]> https://histalk.com/forum/showthread.php?tid=2276 Tue, 10 Mar 2026 13:36:03 +0000 RMcCarthy]]> https://histalk.com/forum/showthread.php?tid=2276 MEDITECH’s Latest AI Innovations Support Smarter Care and Stronger Performance

MEDITECH announced at HIMSS26 that it is expanding its Expanse AI portfolio to further improve the clinician experience, empower patients, and maximize financial performance. One of the most impactful solutions is the introduction of native ambient intelligence for physicians and nurses. 

MEDITECH is extending its support for ambient listening by integrating its native ambient intelligence solutions within the workflows of the Expanse Now mobile app for physicians and Expanse Point of Care app for nurses. These fully integrated solutions reduce documentation burden by capturing conversations in real time, automatically generating clinic visit notes and inpatient assessments, and queuing next steps in workflow.

Additional AI solutions debuting at the conference include:
  • Claim Denial Agents 
  • MyHealth Assistant
  • Ask Expanse

 For more information read the full press release. And, vist MEDITECH at HIMSS26, booth #5031, and at the Interop+Smart Experience Pavilion, booth #12623. ]]> MEDITECH’s Latest AI Innovations Support Smarter Care and Stronger Performance

MEDITECH announced at HIMSS26 that it is expanding its Expanse AI portfolio to further improve the clinician experience, empower patients, and maximize financial performance. One of the most impactful solutions is the introduction of native ambient intelligence for physicians and nurses. 

MEDITECH is extending its support for ambient listening by integrating its native ambient intelligence solutions within the workflows of the Expanse Now mobile app for physicians and Expanse Point of Care app for nurses. These fully integrated solutions reduce documentation burden by capturing conversations in real time, automatically generating clinic visit notes and inpatient assessments, and queuing next steps in workflow.

Additional AI solutions debuting at the conference include:
  • Claim Denial Agents 
  • MyHealth Assistant
  • Ask Expanse

 For more information read the full press release. And, vist MEDITECH at HIMSS26, booth #5031, and at the Interop+Smart Experience Pavilion, booth #12623. ]]> <![CDATA[Medicomp Systems Customer IJN Becomes Malaysia’s First Hospital to HIMSS Stage 7]]> https://histalk.com/forum/showthread.php?tid=2273 Mon, 09 Mar 2026 17:17:01 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2273 Medicomp Systems Customer IJN Becomes Malaysia’s First Hospital to Achieve HIMSS EMRAM Stage 7

Institut Jantung Negara-National Heart Institute’s historic milestone enabled by Medicomp’s Quippe® clinical documentation and intelligence platform

HERNDON, VA, March 9, 2026 — Medicomp Systems, a leading provider of evidence-based clinically intelligent data solutions, today announced that its customer, Institut Jantung Negara (IJN), the National Heart Institute of Malaysia, has achieved Stage 7 validation from the Healthcare Information and Management Systems Society (HIMSS) Electronic Medical Record Adoption Model (EMRAM) — the highest level of digital health maturity recognized by HIMSS. IJN is the first hospital in Malaysia to reach this milestone.

EMRAM Stage 7 represents the pinnacle of electronic medical record (EMR) adoption, requiring hospitals to demonstrate fully paperless operations, robust data analytics capabilities, and the use of clinical data to measurably improve patient outcomes.

IJN, a 433-bed quaternary hospital and the largest integrated cardiovascular and thoracic care center in Asia, partnered with Medicomp and its regional implementation partner APUK Co., Ltd. to deploy Quippe®, Medicomp’s evidence-based clinical documentation and decision support platform. The implementation drove a rapid digital transformation:, IJN achieved 98% adoption of electronic clinical documentation. IJN had previously become the first hospital in Malaysia to achieve EMRAM Stage 6 and has now extended that leadership to the highest tier of certification.

“This achievement is a testament to IJN’s vision, leadership, and commitment to delivering world-class patient care through digital innovation,” said David Lareau, president and CEO of Medicomp Systems. “Quippe was designed to meet clinicians where they are and give them the structured, validated data they need to make the best possible decisions at the point of care. IJN’s Stage 7 achievement is proof that when clinical intelligence and institutional commitment come together, transformational outcomes follow.”

Quippe’s structured clinical data foundation, standardized medical terminology, and dynamic clinical workspace provided the foundation IJN needed to satisfy EMRAM’s rigorous Stage 7 requirements, including advanced clinical decision support, closed-loop medication management, and data-driven outcomes analysis. The platform’s proactive point-of-care alerts enabled clinicians to manage risk more effectively and deliver consistent, high-quality care.

“Becoming Malaysia’s first EMRAM Stage 7 hospital proves what is possible when vision, collaboration, and determination come together,” said Dr. Rhema Sundram, Head of Customer Experience for IJN. “Achieving this milestone demanded meaningful clinical adoption. Quippe provided IJN physicians with a structured yet intuitive documentation platform, strengthening data quality, clinical decision support, and interoperability - key components in reaching EMRAM Stage 7.”

In addition to implementation services, Medicomp’s Bangkok-based global implementation partner, APUK Co., Ltd., provides workflow analysis and ongoing optimization tailored to the needs of IJN and healthcare providers across Southeast Asia.
Medicomp will be showcasing Quippe and its full suite of AI-enabled clinical intelligence tools at HIMSS26, March 9 to 12 in Las Vegas (booth 5435). Live demonstrations are available, and Medicomp strongly recommends reserving demo time in advance at https://medicomp.com/himss26.

About Medicomp Systems
Medicomp Systems delivers the industry’s only comprehensive data foundation and evidence-based clinical intelligence engine, Quippe®, ensuring data usability, accuracy, and trust in health technology systems of tomorrow. Healthcare faces a widening gap between data and clinical understanding — putting patient safety, compliance, and financial performance at risk as health IT complexity and AI adoption increase. Quippe uniquely solves this by connecting information across domains, normalizing inputs, and validating AI outputs — for accurate coding, compliant data, and trustworthy decisions at every point of care. Quippe works seamlessly with any EHR or health tech, driving intelligent clinical workflows that align with how clinicians think and work. Medicomp delivers proven clinical and financial ROI, improved productivity and outcomes, reduced risk, and accurate reimbursement. To learn more, visit https://medicomp.com.

Media Contact:
Medicomp Systems
medicompPR@supremecomms.ai
SOURCE Medicomp Systems]]> Medicomp Systems Customer IJN Becomes Malaysia’s First Hospital to Achieve HIMSS EMRAM Stage 7

Institut Jantung Negara-National Heart Institute’s historic milestone enabled by Medicomp’s Quippe® clinical documentation and intelligence platform

HERNDON, VA, March 9, 2026 — Medicomp Systems, a leading provider of evidence-based clinically intelligent data solutions, today announced that its customer, Institut Jantung Negara (IJN), the National Heart Institute of Malaysia, has achieved Stage 7 validation from the Healthcare Information and Management Systems Society (HIMSS) Electronic Medical Record Adoption Model (EMRAM) — the highest level of digital health maturity recognized by HIMSS. IJN is the first hospital in Malaysia to reach this milestone.

EMRAM Stage 7 represents the pinnacle of electronic medical record (EMR) adoption, requiring hospitals to demonstrate fully paperless operations, robust data analytics capabilities, and the use of clinical data to measurably improve patient outcomes.

IJN, a 433-bed quaternary hospital and the largest integrated cardiovascular and thoracic care center in Asia, partnered with Medicomp and its regional implementation partner APUK Co., Ltd. to deploy Quippe®, Medicomp’s evidence-based clinical documentation and decision support platform. The implementation drove a rapid digital transformation:, IJN achieved 98% adoption of electronic clinical documentation. IJN had previously become the first hospital in Malaysia to achieve EMRAM Stage 6 and has now extended that leadership to the highest tier of certification.

“This achievement is a testament to IJN’s vision, leadership, and commitment to delivering world-class patient care through digital innovation,” said David Lareau, president and CEO of Medicomp Systems. “Quippe was designed to meet clinicians where they are and give them the structured, validated data they need to make the best possible decisions at the point of care. IJN’s Stage 7 achievement is proof that when clinical intelligence and institutional commitment come together, transformational outcomes follow.”

Quippe’s structured clinical data foundation, standardized medical terminology, and dynamic clinical workspace provided the foundation IJN needed to satisfy EMRAM’s rigorous Stage 7 requirements, including advanced clinical decision support, closed-loop medication management, and data-driven outcomes analysis. The platform’s proactive point-of-care alerts enabled clinicians to manage risk more effectively and deliver consistent, high-quality care.

“Becoming Malaysia’s first EMRAM Stage 7 hospital proves what is possible when vision, collaboration, and determination come together,” said Dr. Rhema Sundram, Head of Customer Experience for IJN. “Achieving this milestone demanded meaningful clinical adoption. Quippe provided IJN physicians with a structured yet intuitive documentation platform, strengthening data quality, clinical decision support, and interoperability - key components in reaching EMRAM Stage 7.”

In addition to implementation services, Medicomp’s Bangkok-based global implementation partner, APUK Co., Ltd., provides workflow analysis and ongoing optimization tailored to the needs of IJN and healthcare providers across Southeast Asia.
Medicomp will be showcasing Quippe and its full suite of AI-enabled clinical intelligence tools at HIMSS26, March 9 to 12 in Las Vegas (booth 5435). Live demonstrations are available, and Medicomp strongly recommends reserving demo time in advance at https://medicomp.com/himss26.

About Medicomp Systems
Medicomp Systems delivers the industry’s only comprehensive data foundation and evidence-based clinical intelligence engine, Quippe®, ensuring data usability, accuracy, and trust in health technology systems of tomorrow. Healthcare faces a widening gap between data and clinical understanding — putting patient safety, compliance, and financial performance at risk as health IT complexity and AI adoption increase. Quippe uniquely solves this by connecting information across domains, normalizing inputs, and validating AI outputs — for accurate coding, compliant data, and trustworthy decisions at every point of care. Quippe works seamlessly with any EHR or health tech, driving intelligent clinical workflows that align with how clinicians think and work. Medicomp delivers proven clinical and financial ROI, improved productivity and outcomes, reduced risk, and accurate reimbursement. To learn more, visit https://medicomp.com.

Media Contact:
Medicomp Systems
medicompPR@supremecomms.ai
SOURCE Medicomp Systems]]> <![CDATA[3/18 Webinar: How to Prepare for Healthcare’s Post-OBBBA Era]]> https://histalk.com/forum/showthread.php?tid=2272 Wed, 04 Mar 2026 20:54:37 +0000 RMcCarthy]]> https://histalk.com/forum/showthread.php?tid=2272 Wednesday, March 18, 12:00pm EST: MEDITECH Thought Leader Webinar Series 

CMS (Centers for Medicare & Medicaid Services) is facing significant funding cuts across several programs, including Medicare, Medicaid, and the Affordable Care Act (ACA) Navigator program. These cuts are causing widespread concern among healthcare leaders and clinicians, particularly in rural communities whose healthcare organizations could be disproportionately affected. While the cuts aren't scheduled to take full effect for a year or more, healthcare organizations must begin planning for them now.

This webinar will consider specific strategies for preparing for reimbursement reductions, new enrollment requirements, limits on state provider taxes, and other changes that could have a significant impact on revenue. We'll discuss specific strategies you can begin deploying today to reduce the impact of these cuts and help your organization successfully navigate these uncertain times.
  • Arlan Johnson, Chief Executive Officer, Howard County Medical Center
  • Marc Gibbs,  Chief Information Officer, Meadville Medical Center
  • Rachel Wilkes,  Associate Vice President Marketing, MEDITECH [moderator]

Here are some of the topics we'll cover:
  • The One Big Beautiful Bill Act (OBBBA)
  • The Rural Health Transformation Program (RHTP)
  • Assessing the potential impact to your organization
  • Evaluating/rebalancing your business lines
  • New revenue opportunities under the OBBBA
  • The role of interoperability
  • The importance of strategic partnerships

Note: This will be a 45-minute event with an optional 15 minutes of Q&A for those who can stay online.
Register here.]]> Wednesday, March 18, 12:00pm EST: MEDITECH Thought Leader Webinar Series 

CMS (Centers for Medicare & Medicaid Services) is facing significant funding cuts across several programs, including Medicare, Medicaid, and the Affordable Care Act (ACA) Navigator program. These cuts are causing widespread concern among healthcare leaders and clinicians, particularly in rural communities whose healthcare organizations could be disproportionately affected. While the cuts aren't scheduled to take full effect for a year or more, healthcare organizations must begin planning for them now.

This webinar will consider specific strategies for preparing for reimbursement reductions, new enrollment requirements, limits on state provider taxes, and other changes that could have a significant impact on revenue. We'll discuss specific strategies you can begin deploying today to reduce the impact of these cuts and help your organization successfully navigate these uncertain times.
  • Arlan Johnson, Chief Executive Officer, Howard County Medical Center
  • Marc Gibbs,  Chief Information Officer, Meadville Medical Center
  • Rachel Wilkes,  Associate Vice President Marketing, MEDITECH [moderator]

Here are some of the topics we'll cover:
  • The One Big Beautiful Bill Act (OBBBA)
  • The Rural Health Transformation Program (RHTP)
  • Assessing the potential impact to your organization
  • Evaluating/rebalancing your business lines
  • New revenue opportunities under the OBBBA
  • The role of interoperability
  • The importance of strategic partnerships

Note: This will be a 45-minute event with an optional 15 minutes of Q&A for those who can stay online.
Register here.]]> <![CDATA[Rural hospitals select MEDITECH Expanse to stay independent amidst challenges]]> https://histalk.com/forum/showthread.php?tid=2271 Wed, 04 Mar 2026 17:44:17 +0000 RMcCarthy]]> https://histalk.com/forum/showthread.php?tid=2271 15 rural hospitals sign for Expanse in 2025, maintaining community-focused care

Facing a challenging market defined by financial strain and rising consolidations, independent-minded rural health systems have bucked the trend by turning to MEDITECH Expanse to preserve the autonomy needed to support their communities. Fifteen rural hospitals opted for MEDITECH Expanse in 2025, joining an expanding group of over 250 rural sites operating the web- and cloud-native platform.

“Rural hospitals provide a safety net for nearly 20% of the US population, but several recent policy shifts — including Medicare reimbursement cuts, changes to bad debt reimbursement, and expiration of federal subsidies for the Affordable Care Act — are all threatening these organizations’ razor-thin margins,” said MEDITECH Chief Nursing Executive Cathy Turner, RN. “While these threats have pushed some hospitals towards consolidation, we’re committed to providing solutions and services to help rural health facilities stay self-governed and cater to the unique care needs of their local communities, avoiding the service reductions and cost increases often associated with mergers.”

A growing number of these rural hospitals have turned to MEDITECH’s cloud-native subscription model, MEDITECH as a Service. MaaS delivers an enterprise-level EHR without the significant upfront capital investment or extensive on-premise infrastructure, which is critical for organizations operating with thin margins. MaaS customers receive the same "full-scale" EHR used by larger organizations, rather than a "lite" or scaled-back version. Crucially, it also preserves their operational autonomy, allowing them to tailor workflows for the unique needs of their community instead of being locked into a rigid, one-size-fits-all system shared with other customers or through a larger host system.

For a list of hospitals, read the full release here. ]]> 15 rural hospitals sign for Expanse in 2025, maintaining community-focused care

Facing a challenging market defined by financial strain and rising consolidations, independent-minded rural health systems have bucked the trend by turning to MEDITECH Expanse to preserve the autonomy needed to support their communities. Fifteen rural hospitals opted for MEDITECH Expanse in 2025, joining an expanding group of over 250 rural sites operating the web- and cloud-native platform.

“Rural hospitals provide a safety net for nearly 20% of the US population, but several recent policy shifts — including Medicare reimbursement cuts, changes to bad debt reimbursement, and expiration of federal subsidies for the Affordable Care Act — are all threatening these organizations’ razor-thin margins,” said MEDITECH Chief Nursing Executive Cathy Turner, RN. “While these threats have pushed some hospitals towards consolidation, we’re committed to providing solutions and services to help rural health facilities stay self-governed and cater to the unique care needs of their local communities, avoiding the service reductions and cost increases often associated with mergers.”

A growing number of these rural hospitals have turned to MEDITECH’s cloud-native subscription model, MEDITECH as a Service. MaaS delivers an enterprise-level EHR without the significant upfront capital investment or extensive on-premise infrastructure, which is critical for organizations operating with thin margins. MaaS customers receive the same "full-scale" EHR used by larger organizations, rather than a "lite" or scaled-back version. Crucially, it also preserves their operational autonomy, allowing them to tailor workflows for the unique needs of their community instead of being locked into a rigid, one-size-fits-all system shared with other customers or through a larger host system.

For a list of hospitals, read the full release here. ]]> <![CDATA[Altera Digital Health to Showcase Human-Centered AI and EHR Advancements at HIMSS26]]> https://histalk.com/forum/showthread.php?tid=2270 Tue, 03 Mar 2026 20:41:44 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2270 Altera Digital Health to Unveil Ambient Listening AI at HIMSS25
Health IT leader to showcase solutions enhancements, vision for healthcare at global conference

NIAGARA FALLS, N.Y.-- Altera Digital Health (booth #2532), a global health IT leader, will exhibit at the Health Information Management Systems Society (HIMSS) 2025 Global Conference in Las Vegas, Nevada, March 3–6, 2025. Attendees will have the opportunity to receive demos and learn about new solutions, services and product updates from Altera experts, such as Altera’s ambient listening artificial intelligence (AI) for clinical note documentation, new patient portals and analytics solutions. Altera will also deliver several presentations, including a session on the organization’s vision for the future of healthcare, and host a “Viva Altera” Happy Hour.

Altera’s ambient listening AI tools, developed for Sunrise™, Paragon® Denali, and TouchWorks® EHR, capture a conversation in the exam room, summarize it in the clinical note and extract the unstructured data to create structured documentation. Clients and other attendees can learn how this facilitates more natural patient–provider interactions, decreases documentation burdens for providers, and enhances the accuracy and consistency of clinical note authoring. Altera will also discuss and demo several additional new products and features, including (i) Sunrise CarePath a new patient portal; (ii) Sunrise Health Record, a new HIM solution that captures and integrates unstructured content to consolidate patient records; (iii) a prescription writer tool for Paragon Denali; (iv) a Waypoint interactive assistance tool for TouchWorks EHR users; and (v) CareInTelligence, an analytics solution for dbMotion™ that provides data standardization, visualization and reporting capabilities. Some of the above solutions are planned for general availability later in 2025.

Additionally, Altera subject matter experts will share insights on a range of topics during the following presentations:
  • Make your data work harder: How actionable insights enable better outcomes for your organization. Kevin Ritter, Executive Vice President, CareInMotion, Altera Digital Health, will discuss how advanced analytics will enable organizations to make more informed decisions with greater efficiency. (Tuesday, March 4, 10:30–10:50 a.m., Interop and Smart Experience Pavilion, booth C3318-14, and Wednesday, March 5, 3:00–3:20 p.m., booth #2532.)
  • Shared goals and measured results: Why Altera is doubling down on client outcomes. Ben Scharfe, Executive Vice President, AI, Altera Digital Health, will elaborate on Altera’s vision for the future of healthcare as well as the company’s client-centric approach and evolution. (Tuesday, March 4, 12:00–12:20 p.m., booth #2532.)
  • Revolutionizing healthcare IT: Leveraging AI to enhance efficiency and cost effectiveness at Altera Digital Health. Dr. Bob Taylor, Chief Product Strategist, Altera Digital Health, will discuss how Altera is leveraging Microsoft and EPAM technology to improve operational efficiency, optimize costs and set the stage for future technology modernization. (Wednesday, March 5, 11:00–11:20 a.m., Microsoft booth #2221.)
  • “Cool, but how will it actually work?”: AI complexities in a practical healthcare landscape. Scharfe will provide a realistic roadmap for navigating the complexities of AI integration and showcase real-world applications within Altera's product suite. (Wednesday, March 5, 12:00–12:20 p.m., booth #2532.)
    For the full schedule of Altera’s theater presentations at HIMSS, visit the Altera at HIMSS site.

Altera will also host an in-booth “Viva Altera” Happy Hour on March 4 from 4:30–5:30 p.m. Attendees are welcome to join and discuss industry trends with Altera leaders while enjoying refreshments, light fare and live entertainment, including a DJ and a local magician.

“At Altera, we measure our success based on the outcomes of our clients. Driving positive outcomes by addressing their most pressing needs is the backbone of our vision,” said Marcus Perez, President, Altera Digital Health. “All of the developments we’re highlighting at HIMSS25 are the culmination of our pursuit to better enable clinicians, evolve healthcare organizations and empower patients. I’m excited for our team to connect with clients and partners at the conference to show how we’re bringing this vision to life and elevating healthcare experiences for all.”

Learn how Altera is bringing next-level healthcare within reach by visiting alterahealth.com and stopping by booth #2532 at HIMSS25.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Contacts
Media Contact
AlteraMediaRelations@alterahealth.com]]> Altera Digital Health to Unveil Ambient Listening AI at HIMSS25
Health IT leader to showcase solutions enhancements, vision for healthcare at global conference

NIAGARA FALLS, N.Y.-- Altera Digital Health (booth #2532), a global health IT leader, will exhibit at the Health Information Management Systems Society (HIMSS) 2025 Global Conference in Las Vegas, Nevada, March 3–6, 2025. Attendees will have the opportunity to receive demos and learn about new solutions, services and product updates from Altera experts, such as Altera’s ambient listening artificial intelligence (AI) for clinical note documentation, new patient portals and analytics solutions. Altera will also deliver several presentations, including a session on the organization’s vision for the future of healthcare, and host a “Viva Altera” Happy Hour.

Altera’s ambient listening AI tools, developed for Sunrise™, Paragon® Denali, and TouchWorks® EHR, capture a conversation in the exam room, summarize it in the clinical note and extract the unstructured data to create structured documentation. Clients and other attendees can learn how this facilitates more natural patient–provider interactions, decreases documentation burdens for providers, and enhances the accuracy and consistency of clinical note authoring. Altera will also discuss and demo several additional new products and features, including (i) Sunrise CarePath a new patient portal; (ii) Sunrise Health Record, a new HIM solution that captures and integrates unstructured content to consolidate patient records; (iii) a prescription writer tool for Paragon Denali; (iv) a Waypoint interactive assistance tool for TouchWorks EHR users; and (v) CareInTelligence, an analytics solution for dbMotion™ that provides data standardization, visualization and reporting capabilities. Some of the above solutions are planned for general availability later in 2025.

Additionally, Altera subject matter experts will share insights on a range of topics during the following presentations:
  • Make your data work harder: How actionable insights enable better outcomes for your organization. Kevin Ritter, Executive Vice President, CareInMotion, Altera Digital Health, will discuss how advanced analytics will enable organizations to make more informed decisions with greater efficiency. (Tuesday, March 4, 10:30–10:50 a.m., Interop and Smart Experience Pavilion, booth C3318-14, and Wednesday, March 5, 3:00–3:20 p.m., booth #2532.)
  • Shared goals and measured results: Why Altera is doubling down on client outcomes. Ben Scharfe, Executive Vice President, AI, Altera Digital Health, will elaborate on Altera’s vision for the future of healthcare as well as the company’s client-centric approach and evolution. (Tuesday, March 4, 12:00–12:20 p.m., booth #2532.)
  • Revolutionizing healthcare IT: Leveraging AI to enhance efficiency and cost effectiveness at Altera Digital Health. Dr. Bob Taylor, Chief Product Strategist, Altera Digital Health, will discuss how Altera is leveraging Microsoft and EPAM technology to improve operational efficiency, optimize costs and set the stage for future technology modernization. (Wednesday, March 5, 11:00–11:20 a.m., Microsoft booth #2221.)
  • “Cool, but how will it actually work?”: AI complexities in a practical healthcare landscape. Scharfe will provide a realistic roadmap for navigating the complexities of AI integration and showcase real-world applications within Altera's product suite. (Wednesday, March 5, 12:00–12:20 p.m., booth #2532.)
    For the full schedule of Altera’s theater presentations at HIMSS, visit the Altera at HIMSS site.

Altera will also host an in-booth “Viva Altera” Happy Hour on March 4 from 4:30–5:30 p.m. Attendees are welcome to join and discuss industry trends with Altera leaders while enjoying refreshments, light fare and live entertainment, including a DJ and a local magician.

“At Altera, we measure our success based on the outcomes of our clients. Driving positive outcomes by addressing their most pressing needs is the backbone of our vision,” said Marcus Perez, President, Altera Digital Health. “All of the developments we’re highlighting at HIMSS25 are the culmination of our pursuit to better enable clinicians, evolve healthcare organizations and empower patients. I’m excited for our team to connect with clients and partners at the conference to show how we’re bringing this vision to life and elevating healthcare experiences for all.”

Learn how Altera is bringing next-level healthcare within reach by visiting alterahealth.com and stopping by booth #2532 at HIMSS25.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Contacts
Media Contact
AlteraMediaRelations@alterahealth.com]]> <![CDATA[Linus Health to Present New Findings at Global Alzheimer’s & Parkinson’s Conference]]> https://histalk.com/forum/showthread.php?tid=2269 Tue, 03 Mar 2026 20:25:29 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2269 Linus Health to Present New Findings on Digital Risk Scores for Dementia and Patient-Centered Endpoints at Leading Global Alzheimer’s and Parkinson’s Conference
BOSTON, March 3, 2026 – Linus Health will present new research at a leading global Alzheimer’s and Parkinson’s Diseases conference, revealing how advanced insights from digital cognitive assessments and personalized outcome measures may help transform how patients are identified for emerging therapies and how treatment impact is measured in ways that reflect patients’ personal priorities.

This research will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark, and online. AD/PD convenes thousands of scientists, clinicians, and industry leaders to share the latest advances in basic science, translational research, clinical insights, and therapeutic innovation.

Linus Health will present three poster presentations highlighting the growing role of multimodal digital assessments in accelerating research across Alzheimer’s disease and related disorders.

Identifying Candidates for Disease-Modifying Therapies
All of the posters presented by Linus Health will be available for viewing from March 17 through midday on March 19. Poster locations will be listed in the official AD/PD™ 2026 program and onsite materials.

Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health, will present two posters:

#1367: Identifying Eligible Candidates for Alzheimer’s Disease Modifying Treatment with the Digital Clock and Recall (DCR™) demonstrates that a combination of two complementary multimodal, machine-learning models built from Linus Health DCR process metrics — the DCR Cognition Score and Amyloid Positivity Risk — shows a strong performance in identifying individuals in earlier symptomatic stages (mild cognitive impairment or mild dementia likely due to AD) who may be appropriate candidates for disease-modifying therapies.

#1925: Prediction of Plasma p-tau217 Status and Alzheimer’s Risk with the Remote Ready Digital Assessment of Cognition demonstrates how the Linus Health Digital Assessment of Cognition (DAC) delivers scalable, remote-ready predictions of p-tau217 status and biologically anchored cognitive phenotyping to support trial prescreening and community screening. With high classification accuracy and negative predictive value, the approach performs well as a front-end screener, helping prioritize confirmatory testing and reduce unnecessary biomarker testing for low-likelihood candidates.

“These findings underscore the growing role of digital, biologically anchored cognitive assessments in identifying and stratifying participants for Alzheimer’s research,” said Jannati. “By pairing high-resolution cognitive performance signals with biomarker risk estimation – such as amyloid-PET and plasma p-tau217 – we can more efficiently prioritize who should move to confirmatory testing, reduce unnecessary procedures, and accelerate recruitment while maintaining scientific rigor.”

Elevating Participant Priorities
Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, will present new data exploring how culturally responsive, person-specific outcome measures can be scaled across international Alzheimer’s research settings.

#2179: A Feasibility Study to Assess the Applicability and User Acceptance of the Electronic Person Specific Outcome Measures (ePSOM) in a Japanese Memory Clinic Population. ePSOM is a digital tool that captures what matters most to patients in their daily lives and measures their confidence in maintaining those priorities over time. The study assesses the feasibility and acceptability of the ePSOM tool among Japanese patients with early symptomatic Alzheimer’s disease and explores how individual patient priorities can be incorporated into study endpoints in different cultural settings.

The research builds on prior work in the United Kingdom and the United States and advances understanding of how personalized, patient-centered evaluations can be implemented at scale in international trials.

“As new treatments for Alzheimer’s disease emerge, it is essential that study endpoints incorporate the participant perspective of what matters most across cultures,” said Saunders. “Our results support the feasibility of implementing individualized outcome measures in diverse clinical environments across multiple countries.”

Advancing a Multimodal Approach to Neurodegenerative Research

In addition to the new research, Linus Health will emphasize at AD/PD its broader multimodal platform, which integrates cognitive, speech, and motor assessments to support research across neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease.

By combining data from multiple domains, Linus Health solutions enable life sciences organizations to efficiently identify potential participants for clinical trials of new brain health therapies. The platform also enables researchers and clinicians to develop composite digital endpoints that support earlier detection, more precise stratification, and longitudinal tracking across disease stages.

Conference attendees are invited to set up time to meet with the Linus Health team onsite in Copenhagen.

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people around the world. By advancing how we detect and address cognitive and brain disorders leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence, the company’s goal is to enable a future where people can live longer, healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a practical means of enabling early detection, empowers providers and researchers with actionable insights, and supports individuals with personalized action plans. The company partners with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow Linus Health on LinkedIn.

Media Contact:
Tara Stultz (Supreme Communications for Linus Health)
tstultz@acmarketingpr.com]]> Linus Health to Present New Findings on Digital Risk Scores for Dementia and Patient-Centered Endpoints at Leading Global Alzheimer’s and Parkinson’s Conference
BOSTON, March 3, 2026 – Linus Health will present new research at a leading global Alzheimer’s and Parkinson’s Diseases conference, revealing how advanced insights from digital cognitive assessments and personalized outcome measures may help transform how patients are identified for emerging therapies and how treatment impact is measured in ways that reflect patients’ personal priorities.

This research will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark, and online. AD/PD convenes thousands of scientists, clinicians, and industry leaders to share the latest advances in basic science, translational research, clinical insights, and therapeutic innovation.

Linus Health will present three poster presentations highlighting the growing role of multimodal digital assessments in accelerating research across Alzheimer’s disease and related disorders.

Identifying Candidates for Disease-Modifying Therapies
All of the posters presented by Linus Health will be available for viewing from March 17 through midday on March 19. Poster locations will be listed in the official AD/PD™ 2026 program and onsite materials.

Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health, will present two posters:

#1367: Identifying Eligible Candidates for Alzheimer’s Disease Modifying Treatment with the Digital Clock and Recall (DCR™) demonstrates that a combination of two complementary multimodal, machine-learning models built from Linus Health DCR process metrics — the DCR Cognition Score and Amyloid Positivity Risk — shows a strong performance in identifying individuals in earlier symptomatic stages (mild cognitive impairment or mild dementia likely due to AD) who may be appropriate candidates for disease-modifying therapies.

#1925: Prediction of Plasma p-tau217 Status and Alzheimer’s Risk with the Remote Ready Digital Assessment of Cognition demonstrates how the Linus Health Digital Assessment of Cognition (DAC) delivers scalable, remote-ready predictions of p-tau217 status and biologically anchored cognitive phenotyping to support trial prescreening and community screening. With high classification accuracy and negative predictive value, the approach performs well as a front-end screener, helping prioritize confirmatory testing and reduce unnecessary biomarker testing for low-likelihood candidates.

“These findings underscore the growing role of digital, biologically anchored cognitive assessments in identifying and stratifying participants for Alzheimer’s research,” said Jannati. “By pairing high-resolution cognitive performance signals with biomarker risk estimation – such as amyloid-PET and plasma p-tau217 – we can more efficiently prioritize who should move to confirmatory testing, reduce unnecessary procedures, and accelerate recruitment while maintaining scientific rigor.”

Elevating Participant Priorities
Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, will present new data exploring how culturally responsive, person-specific outcome measures can be scaled across international Alzheimer’s research settings.

#2179: A Feasibility Study to Assess the Applicability and User Acceptance of the Electronic Person Specific Outcome Measures (ePSOM) in a Japanese Memory Clinic Population. ePSOM is a digital tool that captures what matters most to patients in their daily lives and measures their confidence in maintaining those priorities over time. The study assesses the feasibility and acceptability of the ePSOM tool among Japanese patients with early symptomatic Alzheimer’s disease and explores how individual patient priorities can be incorporated into study endpoints in different cultural settings.

The research builds on prior work in the United Kingdom and the United States and advances understanding of how personalized, patient-centered evaluations can be implemented at scale in international trials.

“As new treatments for Alzheimer’s disease emerge, it is essential that study endpoints incorporate the participant perspective of what matters most across cultures,” said Saunders. “Our results support the feasibility of implementing individualized outcome measures in diverse clinical environments across multiple countries.”

Advancing a Multimodal Approach to Neurodegenerative Research

In addition to the new research, Linus Health will emphasize at AD/PD its broader multimodal platform, which integrates cognitive, speech, and motor assessments to support research across neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease.

By combining data from multiple domains, Linus Health solutions enable life sciences organizations to efficiently identify potential participants for clinical trials of new brain health therapies. The platform also enables researchers and clinicians to develop composite digital endpoints that support earlier detection, more precise stratification, and longitudinal tracking across disease stages.

Conference attendees are invited to set up time to meet with the Linus Health team onsite in Copenhagen.

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people around the world. By advancing how we detect and address cognitive and brain disorders leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence, the company’s goal is to enable a future where people can live longer, healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a practical means of enabling early detection, empowers providers and researchers with actionable insights, and supports individuals with personalized action plans. The company partners with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow Linus Health on LinkedIn.

Media Contact:
Tara Stultz (Supreme Communications for Linus Health)
tstultz@acmarketingpr.com]]> <![CDATA[FDB Advances Safe Agentic Integrations for Workflow Automation Ahead of HIMSS26]]> https://histalk.com/forum/showthread.php?tid=2268 Mon, 02 Mar 2026 15:25:13 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2268 FDB Advances Safe Agentic Integrations for Workflow Automation with MCP Server and New Intelligent Solutions Ahead of HIMSS26
   
Momentum reinforces FDB's leadership in enabling healthcare organizations to confidently leverage AI and trusted medication intelligence to streamline clinical workflows

SOUTH SAN FRANCISCO, Calif., March 2, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced momentum in pilot adoption of its new Model Context Protocol (MCP) server, now named FDB MedProof MCP™. The company also announced that it is previewing two new intelligent medication workflow automation innovations: FDB Script Agent™, an AI-enabled prescription automation agent designed for ambulatory settings, and FDB VerifyAssist™, an inpatient pharmacy order verification assistant.

Together, these advancements reflect FDB's leadership in helping healthcare vendors and organizations leverage agents grounded in trusted, context-rich medication intelligence from FDB to streamline medication-related clinician and patient workflows as the industry prepares for the 2026 HIMSS Global Health Conference & Exhibition.

A growing number of organizations have been adopting the FDB MedProof MCP server since its introduction in October. This indicates strong market enthusiasm for the new technology as the first AI-native solution that enables technology teams to confidently connect agentic systems and applications to standardized medication intelligence built on decades of trusted drug knowledge and delivered in patient-specific clinical context. FDB MedProof MCP empowers scalable innovation while safeguarding accuracy and trust.

"Healthcare organizations are moving quickly to adopt new AI-driven assistance and automation capabilities, but medication workflows demand a higher standard of safety and accountability," said FDB President David Delaney. "FDB MedProof MCP gives innovators a trusted foundation to accelerate time to value for AI-enabled medication workflow solutions, freeing clinicians to focus on patient care."

One organization leveraging FDB MedProof MCP for AI Agent integrations is Artera, a patient communications leader with a decade of experience and more than 1,000 customers. Artera's platform integrates humans and AI agents to transform patient communications, aiming to make healthcare the top-rated customer service industry by improving access and reducing administrative friction.

"As we continue to explore new AI agent use cases to drive additional value for our customers, FDB's MCP server is proving to be a critical unlock," said Zach Wood, Chief Product and Strategy Officer, Artera. "By providing secure, standardized access to essential medication-related data during the prototyping phase, it allows us to rapidly validate high-impact agentic AI solutions while reinforcing the trust and accuracy required for healthcare."

Streamlining Ambulatory Prescribing with Auto-Queued Medication Orders

FDB is also beginning to introduce its own purpose-built AI agents governed by FDB to address common, high-friction aspects of medication workflows.

For example, FDB Script Agent is a new AI-empowered prescription automation agent designed for ambulatory care settings, where clinicians often spend significant time manually entering structured prescription orders after patient encounters. Available via MCP or API integration and anchored in validated FDB medication intelligence, Script Agent advances ambient listening to the next level by taking action. It uses spoken information captured during patient visits to auto-queue structured prescription orders directly into the electronic health record (EHR) for clinician review and approval.

An early adopter planning to use the agent is targeting a 70% reduction in documentation time associated with the status quo manual prescribing workflow, helping their clinicians stay focused on patient care while improving workflow efficiency. Additionally, FDB's agent will serve key roles through feature differentiation and revenue growth via user adoption of their premium-priced ambient listening product tier. Select EHR vendors are leveraging Script Agent, with broader availability planned as pilots progress.

Faster, More Informed Medication Verification

FDB is also introducing VerifyAssist, a workflow assistant designed to reduce the burden of medication order verification, which can take 30% to 40% of a hospital pharmacist's time. FDB VerifyAssist automatically surfaces the most important drug-specific verification criteria against each patient's current clinical data (e.g., relevant lab results, age, and other factors) at the point of verification. This helps hospital pharmacists quickly identify orders that warrant closer review.

Automation introduced by VerifyAssist minimizes unnecessary chart navigation and reduces cognitive load for hospital pharmacists while supporting regulatory and patient safety compliance. By freeing pharmacists from repetitive manual checks, organizations can redirect clinical expertise toward direct patient care, medication optimization, and higher value clinical activities.

Building Momentum Toward HIMSS26

FDB will highlight MedProof MCP, Script Agent, and VerifyAssist at HIMSS26, demonstrating how trusted medication intelligence, automation, and emerging standards can work together to improve medication safety, workflow efficiency, and clinician experience.

"These advancements represent the next phase of FDB's evolution, moving beyond data delivery to more intelligent, workflow-integrated solutions," said Virginia Halsey, senior vice president of strategy and product management at FDB. "As healthcare organizations look to define their future with clinical intelligence and automation, FDB is helping ensure that medication decisions remain grounded in the most trusted drug knowledge available."

Learn more by visiting FDB Booth #3235 at HIMSS26.

About FDB

FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health

The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies – FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health – elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> FDB Advances Safe Agentic Integrations for Workflow Automation with MCP Server and New Intelligent Solutions Ahead of HIMSS26
   
Momentum reinforces FDB's leadership in enabling healthcare organizations to confidently leverage AI and trusted medication intelligence to streamline clinical workflows

SOUTH SAN FRANCISCO, Calif., March 2, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced momentum in pilot adoption of its new Model Context Protocol (MCP) server, now named FDB MedProof MCP™. The company also announced that it is previewing two new intelligent medication workflow automation innovations: FDB Script Agent™, an AI-enabled prescription automation agent designed for ambulatory settings, and FDB VerifyAssist™, an inpatient pharmacy order verification assistant.

Together, these advancements reflect FDB's leadership in helping healthcare vendors and organizations leverage agents grounded in trusted, context-rich medication intelligence from FDB to streamline medication-related clinician and patient workflows as the industry prepares for the 2026 HIMSS Global Health Conference & Exhibition.

A growing number of organizations have been adopting the FDB MedProof MCP server since its introduction in October. This indicates strong market enthusiasm for the new technology as the first AI-native solution that enables technology teams to confidently connect agentic systems and applications to standardized medication intelligence built on decades of trusted drug knowledge and delivered in patient-specific clinical context. FDB MedProof MCP empowers scalable innovation while safeguarding accuracy and trust.

"Healthcare organizations are moving quickly to adopt new AI-driven assistance and automation capabilities, but medication workflows demand a higher standard of safety and accountability," said FDB President David Delaney. "FDB MedProof MCP gives innovators a trusted foundation to accelerate time to value for AI-enabled medication workflow solutions, freeing clinicians to focus on patient care."

One organization leveraging FDB MedProof MCP for AI Agent integrations is Artera, a patient communications leader with a decade of experience and more than 1,000 customers. Artera's platform integrates humans and AI agents to transform patient communications, aiming to make healthcare the top-rated customer service industry by improving access and reducing administrative friction.

"As we continue to explore new AI agent use cases to drive additional value for our customers, FDB's MCP server is proving to be a critical unlock," said Zach Wood, Chief Product and Strategy Officer, Artera. "By providing secure, standardized access to essential medication-related data during the prototyping phase, it allows us to rapidly validate high-impact agentic AI solutions while reinforcing the trust and accuracy required for healthcare."

Streamlining Ambulatory Prescribing with Auto-Queued Medication Orders

FDB is also beginning to introduce its own purpose-built AI agents governed by FDB to address common, high-friction aspects of medication workflows.

For example, FDB Script Agent is a new AI-empowered prescription automation agent designed for ambulatory care settings, where clinicians often spend significant time manually entering structured prescription orders after patient encounters. Available via MCP or API integration and anchored in validated FDB medication intelligence, Script Agent advances ambient listening to the next level by taking action. It uses spoken information captured during patient visits to auto-queue structured prescription orders directly into the electronic health record (EHR) for clinician review and approval.

An early adopter planning to use the agent is targeting a 70% reduction in documentation time associated with the status quo manual prescribing workflow, helping their clinicians stay focused on patient care while improving workflow efficiency. Additionally, FDB's agent will serve key roles through feature differentiation and revenue growth via user adoption of their premium-priced ambient listening product tier. Select EHR vendors are leveraging Script Agent, with broader availability planned as pilots progress.

Faster, More Informed Medication Verification

FDB is also introducing VerifyAssist, a workflow assistant designed to reduce the burden of medication order verification, which can take 30% to 40% of a hospital pharmacist's time. FDB VerifyAssist automatically surfaces the most important drug-specific verification criteria against each patient's current clinical data (e.g., relevant lab results, age, and other factors) at the point of verification. This helps hospital pharmacists quickly identify orders that warrant closer review.

Automation introduced by VerifyAssist minimizes unnecessary chart navigation and reduces cognitive load for hospital pharmacists while supporting regulatory and patient safety compliance. By freeing pharmacists from repetitive manual checks, organizations can redirect clinical expertise toward direct patient care, medication optimization, and higher value clinical activities.

Building Momentum Toward HIMSS26

FDB will highlight MedProof MCP, Script Agent, and VerifyAssist at HIMSS26, demonstrating how trusted medication intelligence, automation, and emerging standards can work together to improve medication safety, workflow efficiency, and clinician experience.

"These advancements represent the next phase of FDB's evolution, moving beyond data delivery to more intelligent, workflow-integrated solutions," said Virginia Halsey, senior vice president of strategy and product management at FDB. "As healthcare organizations look to define their future with clinical intelligence and automation, FDB is helping ensure that medication decisions remain grounded in the most trusted drug knowledge available."

Learn more by visiting FDB Booth #3235 at HIMSS26.

About FDB

FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health

The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies – FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health – elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> <![CDATA[FDB Vela™ and Photon Collaborate]]> https://histalk.com/forum/showthread.php?tid=2267 Fri, 27 Feb 2026 13:40:15 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2267 FDB Vela™ and Photon Collaborate to Expand Cost Transparency and Patient Choice in ePrescribing
Integration will broaden pharmacy connectivity and enhance prescription routing to support a more modern, patient-oriented prescribing experience.

SOUTH SAN FRANCISCO and BROOKLYN, NY, February 27, 2026 — FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, and Photon Health (Photon), an innovative prescription platform that empowers patients with medication choice and transparency, today announced an agreement to connect the FDB Vela™ ePrescribing Network with Photon’s digital prescription marketplace. This collaboration will extend the reach and automation of the patient-facing marketplace experience, bringing greater transparency and choice in prescription routing to more patients and providers nationwide.

FDB has built FDB Vela into a robust, cloud-native, HITRUST-certified network designed to enable the seamless exchange of prescription information among prescribers, pharmacies, and payers. Photon will integrate with FDB Vela to enhance prescription routing, broaden pharmacy connectivity, and support a more modern, patient-oriented prescribing experience.

“Electronic prescribing infrastructure should facilitate transparency and innovation across the healthcare ecosystem,” said David Delaney, MD, president of FDB. “By collaborating with Photon, we are extending the reach of FDB Vela and advancing a more open, interoperable network environment that empowers prescribers with options and information and gives patients greater visibility into their prescriptions and out-of-pocket costs.”

Photon’s marketplace enables patients to compare pharmacy options based on factors such as price, convenience, and availability within their digital journey. By connecting to FDB Vela, Photon strengthens its ability to route prescriptions efficiently while maintaining a patient-centric experience that empowers informed decision-making before a patient arrives at the pharmacy counter.

“Prescription networks should exist to serve patients and providers openly,” said Otto Sipe, CEO and co-founder of Photon. “Our collaboration with FDB Vela reflects a shared commitment to modernizing ePrescribing infrastructure, expanding network choice, and delivering greater transparency across the prescription experience.”

The integration combines Photon’s modern ePrescribing platform with FDB Vela’s secure, scalable connectivity, which is built on a cloud-based architecture designed to support 24/7 availability and full redundancy. These industry-trusted capabilities help safeguard the transmission of prescriptions during network interruptions and mitigate single points of failure.

In addition to expanding network connectivity, FDB Vela is building a suite of provider solutions that gives prescribers real-time clinical decision support, specialty prescription routing, workflow automation, and the contextual information they need at the exact moment a prescription is written. These services align with Photon’s focus on delivering timely, relevant information to both providers and patients at the moment prescribing decisions are made.

FDB Vela and Photon are building a prescribing experience that works better for everyone. Photon’s modern prescribing platform combined with FDB Vela’s seamless, secure connectivity between prescribers, payers, and pharmacies creates a full-stack solution that supports a smarter prescribing process and helps reduce the likelihood that patients experience unexpected costs or delays at the pharmacy counter.

Together, FDB Vela and Photon are strengthening an infrastructure that promotes transparency, operational efficiency, and patient choice across the prescribing continuum.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Photon Health
Photon Health is a healthcare technology company that powers transparent and patient-centered prescription experiences. Its platform enables patients to evaluate pharmacy fulfillment options based on price, convenience, and availability, while reducing administrative burden for clinical teams. Photon is focused on increasing access to affordable medications by building a transparent prescription marketplace that connects prescribers, pharmacies, and patients through modern digital infrastructure. To learn more, visit Photon’s website or follow them on LinkedIn.

Media Contacts
Supreme Communications for FDB
FDBPR@supremecomms.ai

Photon Communications
marketing@photon.health]]> FDB Vela™ and Photon Collaborate to Expand Cost Transparency and Patient Choice in ePrescribing
Integration will broaden pharmacy connectivity and enhance prescription routing to support a more modern, patient-oriented prescribing experience.

SOUTH SAN FRANCISCO and BROOKLYN, NY, February 27, 2026 — FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, and Photon Health (Photon), an innovative prescription platform that empowers patients with medication choice and transparency, today announced an agreement to connect the FDB Vela™ ePrescribing Network with Photon’s digital prescription marketplace. This collaboration will extend the reach and automation of the patient-facing marketplace experience, bringing greater transparency and choice in prescription routing to more patients and providers nationwide.

FDB has built FDB Vela into a robust, cloud-native, HITRUST-certified network designed to enable the seamless exchange of prescription information among prescribers, pharmacies, and payers. Photon will integrate with FDB Vela to enhance prescription routing, broaden pharmacy connectivity, and support a more modern, patient-oriented prescribing experience.

“Electronic prescribing infrastructure should facilitate transparency and innovation across the healthcare ecosystem,” said David Delaney, MD, president of FDB. “By collaborating with Photon, we are extending the reach of FDB Vela and advancing a more open, interoperable network environment that empowers prescribers with options and information and gives patients greater visibility into their prescriptions and out-of-pocket costs.”

Photon’s marketplace enables patients to compare pharmacy options based on factors such as price, convenience, and availability within their digital journey. By connecting to FDB Vela, Photon strengthens its ability to route prescriptions efficiently while maintaining a patient-centric experience that empowers informed decision-making before a patient arrives at the pharmacy counter.

“Prescription networks should exist to serve patients and providers openly,” said Otto Sipe, CEO and co-founder of Photon. “Our collaboration with FDB Vela reflects a shared commitment to modernizing ePrescribing infrastructure, expanding network choice, and delivering greater transparency across the prescription experience.”

The integration combines Photon’s modern ePrescribing platform with FDB Vela’s secure, scalable connectivity, which is built on a cloud-based architecture designed to support 24/7 availability and full redundancy. These industry-trusted capabilities help safeguard the transmission of prescriptions during network interruptions and mitigate single points of failure.

In addition to expanding network connectivity, FDB Vela is building a suite of provider solutions that gives prescribers real-time clinical decision support, specialty prescription routing, workflow automation, and the contextual information they need at the exact moment a prescription is written. These services align with Photon’s focus on delivering timely, relevant information to both providers and patients at the moment prescribing decisions are made.

FDB Vela and Photon are building a prescribing experience that works better for everyone. Photon’s modern prescribing platform combined with FDB Vela’s seamless, secure connectivity between prescribers, payers, and pharmacies creates a full-stack solution that supports a smarter prescribing process and helps reduce the likelihood that patients experience unexpected costs or delays at the pharmacy counter.

Together, FDB Vela and Photon are strengthening an infrastructure that promotes transparency, operational efficiency, and patient choice across the prescribing continuum.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Photon Health
Photon Health is a healthcare technology company that powers transparent and patient-centered prescription experiences. Its platform enables patients to evaluate pharmacy fulfillment options based on price, convenience, and availability, while reducing administrative burden for clinical teams. Photon is focused on increasing access to affordable medications by building a transparent prescription marketplace that connects prescribers, pharmacies, and patients through modern digital infrastructure. To learn more, visit Photon’s website or follow them on LinkedIn.

Media Contacts
Supreme Communications for FDB
FDBPR@supremecomms.ai

Photon Communications
marketing@photon.health]]> <![CDATA[Bizmatics is headed to PainConnect!]]> https://histalk.com/forum/showthread.php?tid=2266 Thu, 26 Feb 2026 20:22:23 +0000 Jasmine Torres]]> https://histalk.com/forum/showthread.php?tid=2266 PainConnect from March 5-8, 2026!

Stop by Booth #9 to discover how our EHR Solution, PrognoCIS, empowers pain management providers to streamline documentation, support compliant prescribing, boost workflow efficiency, and elevate clinical decision‑making with built‑in AI tools. Connect with our team, explore the latest features, and get answers to all your questions.



[Image: PainConnect.png]]]> PainConnect from March 5-8, 2026!

Stop by Booth #9 to discover how our EHR Solution, PrognoCIS, empowers pain management providers to streamline documentation, support compliant prescribing, boost workflow efficiency, and elevate clinical decision‑making with built‑in AI tools. Connect with our team, explore the latest features, and get answers to all your questions.



[Image: PainConnect.png]]]> <![CDATA[Health Systems Take the Stage at HIMSS26 to Share Real-World Medication Stories]]> https://histalk.com/forum/showthread.php?tid=2265 Thu, 26 Feb 2026 15:49:10 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2265 Health Systems Take the Stage at HIMSS26 to Share Real-World Medication Intelligence Success Stories
  
ChristianaCare and St. Mary's Healthcare to highlight practical strategies using FDB's Meducation® Solution and FDB AlertSpace® to improve patient medication understanding & safe medication ordering

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced that two health systems leveraging FDB solutions will present real-world case studies at the 2026 HIMSS Global Conference & Exhibition. This will showcase how trusted, patient-specific medication intelligence embedded in the workflow can strengthen patient understanding of their treatments and support safer medication ordering across diverse healthcare settings.

Through two featured education sessions, leaders from ChristianaCare, Delaware's largest health system, and St. Mary's Healthcare, an independent rural, safety-net health system in Amsterdam, New York, will share practical strategies for advancing health literacy through medication education, and for optimizing clinical decision support to improve Leapfrog safe medication ordering performance and clinician experience. 

In HIMSS26 Education Session #17 Smart Medication Management: Bridging Technology with Patient Understanding, Greg O'Neill, director of patient and family health education at ChristianaCare, will discuss how health literacy emerged as a critical patient safety priority at discharge, where medication confusion can undermine adherence and outcomes.

Joined by Kristen Callaghan, nursing professional development specialist, patient and family health education at ChristianaCare, O'Neill will describe how the health system reimagined medication education through a patient-centered, EHR-integrated approach facilitated by FDB's Meducation® solution.

The session will explore how personalized, multilingual medication calendars—using plain language, pictograms, and clear clinical indications—improved patient comprehension, discharge readiness, and equity. Speakers will also share implementation lessons, clinician training strategies, and design considerations that other health systems can adapt to strengthen medication reconciliation and transitions of care.

Attendees can join the ChristianaCare session on Tuesday, March 10, from 10:15 a.m. to 11:15 a.m. PDT, at the Venetian, Level 5, Palazzo M.

In HIMSS26 Education Session #218 A Rural Health System's Leapfrog Improvement Using Smarter Medication Guidance, Julie Demaree, vice president, chief technology and digital innovation officer at St. Mary's Healthcare, will share how the independent rural health system worked to maintain community trust in care quality and safety without the infrastructure of a large health system.

Demaree will be joined by Josh Baker, director of pharmacy, and Michael LeBlanc, clinical pharmacy manager, who will describe how the organization used analytics and clinical decision support optimization facilitated by FDB AlertSpace® to improve computerized physician order entry (CPOE) performance and streamline medication alerts.

The session traces St. Mary's journey to surpassing the average Leapfrog test score for safe medication ordering, achieving a CPOE rate of more than 95%, and significantly reducing alert overrides while preserving clinician confidence and satisfaction. Attendees will gain insight into governance models and replicable strategies for improving medication safety and workflow efficiency in resource-constrained environments.

The St. Mary's Healthcare session will take place on Thursday, March 12, from 2:00 p.m. to 3:00 p.m. PDT, at the Venetian, Level 3, San Polo 3404.

FDB is leading discussions with healthcare organizations at HIMSS26 about how advanced medication intelligence, built on decades of trusted drug knowledge and delivered in patient-specific clinical context, can reduce unnecessary complexity, freeing clinicians to focus fully on patient care.

"When health systems share how they're applying trusted medication intelligence to improve understanding, streamline workflows, and strengthen decision-making, they demonstrate what's possible when the right knowledge is embedded thoughtfully into care," said Virginia Halsey, senior vice president of strategy and product management at FDB. "We're honored to spotlight their leadership and real-world impact at HIMSS26."

Visit FDB at HIMSS26 Booth #3235 to learn more about "Intelligence to Free Your Mind."

Schedule a meeting with FDB at HIMSS26 here.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai
SOURCE FDB (First Databank)]]> Health Systems Take the Stage at HIMSS26 to Share Real-World Medication Intelligence Success Stories
  
ChristianaCare and St. Mary's Healthcare to highlight practical strategies using FDB's Meducation® Solution and FDB AlertSpace® to improve patient medication understanding & safe medication ordering

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced that two health systems leveraging FDB solutions will present real-world case studies at the 2026 HIMSS Global Conference & Exhibition. This will showcase how trusted, patient-specific medication intelligence embedded in the workflow can strengthen patient understanding of their treatments and support safer medication ordering across diverse healthcare settings.

Through two featured education sessions, leaders from ChristianaCare, Delaware's largest health system, and St. Mary's Healthcare, an independent rural, safety-net health system in Amsterdam, New York, will share practical strategies for advancing health literacy through medication education, and for optimizing clinical decision support to improve Leapfrog safe medication ordering performance and clinician experience. 

In HIMSS26 Education Session #17 Smart Medication Management: Bridging Technology with Patient Understanding, Greg O'Neill, director of patient and family health education at ChristianaCare, will discuss how health literacy emerged as a critical patient safety priority at discharge, where medication confusion can undermine adherence and outcomes.

Joined by Kristen Callaghan, nursing professional development specialist, patient and family health education at ChristianaCare, O'Neill will describe how the health system reimagined medication education through a patient-centered, EHR-integrated approach facilitated by FDB's Meducation® solution.

The session will explore how personalized, multilingual medication calendars—using plain language, pictograms, and clear clinical indications—improved patient comprehension, discharge readiness, and equity. Speakers will also share implementation lessons, clinician training strategies, and design considerations that other health systems can adapt to strengthen medication reconciliation and transitions of care.

Attendees can join the ChristianaCare session on Tuesday, March 10, from 10:15 a.m. to 11:15 a.m. PDT, at the Venetian, Level 5, Palazzo M.

In HIMSS26 Education Session #218 A Rural Health System's Leapfrog Improvement Using Smarter Medication Guidance, Julie Demaree, vice president, chief technology and digital innovation officer at St. Mary's Healthcare, will share how the independent rural health system worked to maintain community trust in care quality and safety without the infrastructure of a large health system.

Demaree will be joined by Josh Baker, director of pharmacy, and Michael LeBlanc, clinical pharmacy manager, who will describe how the organization used analytics and clinical decision support optimization facilitated by FDB AlertSpace® to improve computerized physician order entry (CPOE) performance and streamline medication alerts.

The session traces St. Mary's journey to surpassing the average Leapfrog test score for safe medication ordering, achieving a CPOE rate of more than 95%, and significantly reducing alert overrides while preserving clinician confidence and satisfaction. Attendees will gain insight into governance models and replicable strategies for improving medication safety and workflow efficiency in resource-constrained environments.

The St. Mary's Healthcare session will take place on Thursday, March 12, from 2:00 p.m. to 3:00 p.m. PDT, at the Venetian, Level 3, San Polo 3404.

FDB is leading discussions with healthcare organizations at HIMSS26 about how advanced medication intelligence, built on decades of trusted drug knowledge and delivered in patient-specific clinical context, can reduce unnecessary complexity, freeing clinicians to focus fully on patient care.

"When health systems share how they're applying trusted medication intelligence to improve understanding, streamline workflows, and strengthen decision-making, they demonstrate what's possible when the right knowledge is embedded thoughtfully into care," said Virginia Halsey, senior vice president of strategy and product management at FDB. "We're honored to spotlight their leadership and real-world impact at HIMSS26."

Visit FDB at HIMSS26 Booth #3235 to learn more about "Intelligence to Free Your Mind."

Schedule a meeting with FDB at HIMSS26 here.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai
SOURCE FDB (First Databank)]]> <![CDATA[FDB Emphasizes Medication Intelligence for AI and Clinical Workflows at HIMSS 2026]]> https://histalk.com/forum/showthread.php?tid=2264 Thu, 26 Feb 2026 15:39:53 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2264 FDB Emphasizes Medication Intelligence for AI and Clinical Workflows at HIMSS 2026
 
Next-generation medication intelligence and immersive booth experiences anchor FDB presence at the 2026 HIMSS Global Health Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 -- FDB (First Databank), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will bring its vision of "Intelligence to Free Your Mind" to the 2026 HIMSS Global Health Conference & Exhibition at the Venetian Convention & Expo Center in Las Vegas. At HIMSS26, FDB will highlight how its medication intelligence—built on decades of trusted drug knowledge and delivered in patient-specific clinical context—reduces cognitive burden, restores focus, and strengthens both human and AI-enabled workflows. Across solution demonstrations, interactive exhibit-floor experiences, and hosted events, the company will showcase how it is advancing medication intelligence embedded in clinical workflows to support clarity, confidence, and consistency at scale.

FDB will also engage health technology leaders at HIMSS26 in conversations about how validated, context-rich medication intelligence enhances AI performance, establishes analytics integrity, supports workflow automation, and reduces the burden of maintaining complex drug logic internally.

"As AI capabilities expand, analytics grow more sophisticated, and digital health solutions move closer to clinical decision-making, medication data alone is no longer sufficient," said Virginia Halsey, vice president of strategy and product management at FDB. "Advanced medication intelligence, powered by trusted, patient-specific drug knowledge, is now foundational to modern health technology platforms."

Through innovations including its Model Context Protocol (MCP), now called FDB MedProof MCP™, FDB is helping technology teams confidently connect agentic systems and applications to standardized, patient-specific medication intelligence—enabling scalable innovation while safeguarding accuracy and trust.

Step into Calm with Medication Intelligence to Free Your Mind

At booth #3235, FDB will invite HIMSS26 attendees to step into calm and experience what less noise and clearer focus look like in practice. Demonstrations will show how medication intelligence, applied consistently across prescribing, pharmacy verification, medication decision support, and patient education, can reduce unnecessary steps, minimize interruptions, and help clinicians think more clearly within the flow of care.

FDB will highlight solutions that many health systems already rely on as the foundation of safe medication use:

FDB MedKnowledge® delivers the clinically robust drug knowledge that serves as the foundation for FDB's medication intelligence across clinical workflows, giving clinicians certainty when it matters most. FDB Meducation and FDB Meducation Bedside also support safe medication use plus adherence to treatment regimens by enabling clinicians to more easily provide patients with clear, personalized medication instructions at discharge and at the bedside.

FDB AlertSpace® 2.0 introduces the next evolution of the trusted solution, helping healthcare organizations reduce generalized, non-actionable alerts that distract clinicians from patient care and contribute to alert fatigue. Building on the collaborative alert customization capabilities health systems rely on, the new version delivers a modern user experience and scalable architecture for faster adoption and continuous improvement. Embedded analytics and community insights enable teams to evaluate alert performance, acceptance rates, and peer benchmarks within the workflow, while a centralized workspace strengthens governance and change management. An integrated AI Copilot further accelerates time to value by providing access to trusted guidance directly within the platform.

HIMSS26 attendees can further explore the next generation of clinical decision support (CDS) through FDB PatientFirst™ solutions. For patient-specific precision, FDB Targeted Medication Warnings™ and FDB Pharmacogenomic CDS help ensure fewer interruptions and clearer decisions by delivering alerts that reflect each patient's unique clinical context.

On the operations side, FDB Vela™ demonstrates how a modern ePrescribing network can support connected, resilient medication workflows with no single point of failure, while empowering innovation in electronic prescribing.

Agentic & Automation Innovations Unveiled

As healthcare organizations look beyond optimizing individual workflows toward safely scaling AI and automation, FDB will showcase at HIMSS26 how it is building on its medication intelligence foundation with new infrastructure designed for governance, resilience, and long-term flexibility.

FDB will highlight FDB MedProof MCP, the first AI-native server solution that anchors healthcare agents in trusted, current, accountable medication intelligence for CDS. Serving as an agentic orchestration layer that increases speed to market and reduces ongoing maintenance, the MCP enables health tech leaders to standardize how medication intelligence is governed, accessed, and applied across scalable AI-enabled workflows

FDB will also preview its own purpose-built workflow automation innovations that apply medication intelligence to reduce manual effort while preserving clinical judgment. FDB Script Agent™, the company's new AI-empowered prescription automation agent, is designed for ambulatory care settings, where clinicians often spend significant time manually entering structured prescription orders after patient encounters. Available via MCP or API integration and anchored in validated FDB medication intelligence, Script Agent advances ambient listening to the next level by taking action. It uses spoken information captured during patient visits to auto-queue structured prescription orders directly into the electronic health record (EHR) for clinician review and approval.

In addition, FDB will preview FDB VerifyAssist™, a workflow assistant designed to reduce the burden of medication order verification, which can take 30% to 40% of a hospital pharmacist's time. FDB VerifyAssist automatically surfaces the most important drug-specific verification criteria against each patient's current clinical data (e.g., relevant lab results, age, and other factors) at the point of verification. This helps hospital pharmacists quickly identify orders that warrant closer review.

Another persistent, time-consuming challenge confronting clinicians is accurately reconciling a patient's medication list at every transition of care. Incomplete histories create risk. At HIMSS26, FDB will demonstrate how its EHR-integrated medication reconciliation solution, powered by trusted medication intelligence, supports safety checks and helps clinicians create and maintain accurate, consistent medication lists across the flow of care.

Together, these solutions illustrate how FDB is moving from point optimizations toward a system-level approach that lets intelligence carry more of the load across the end-to-end medication workflow.

Learn More in Daily FDB-Hosted Micro-Sessions

Throughout the conference, FDB experts will host short, focused micro-sessions at booth #3235. These sessions will help attendees discover how specific capabilities reduce manual effort, improve consistency, and ease cognitive load across medication-related workflows.

FDB's Agentic Innovations
How FDB powers agentic workflows with medication intelligence, featuring FDB Script Agent and MCP
Tuesday, March 10: 10:30 a.m. and 1:00 p.m.
Wednesday, March 11: 10:30 a.m. and 1:00 p.m.
Thursday, March 12: 10:30 a.m.

FDB's Medication Intelligence Innovations
When medication information is not clear upfront, reconciliation and verification turn into detective work, featuring FDB Medication Reconciliation and VerifyAssist
Tuesday, March 10: 11:30 a.m. and 2 p.m.
Wednesday March 11: 11:30 a.m. and 2 p.m.
Thursday, March 12: 11:30 a.m.

Attendees may inquire within the booth to schedule private sessions at a preferred time.

Calm Continues at Happy Hour

Extending its Intelligence to Free Your Mind theme, FDB will host "Calm Continues at Happy Hour" on Wednesday, March 11, from 4:00 to 5:30 p.m. at its exhibit booth. The reception offers attendees a space to pause, connect with peers, and continue meaningful conversations in a relaxed setting on the exhibit floor.

Guests will be served beer, wine, and soft drinks, along with curated cheese boards and macaron towers. Attendees will also receive a gift package of Greyston Bakery chocolate fudge brownies or chocolate chip blondies.

Recharge and Refresh through Restorative Booth Experiences

FDB invites HIMSS26 attendees to visit the FDB booth to experience restorative activities designed to embrace the spirit of calm. Complimentary foot and shoulder massage stations and infused water will be available to provide a brief respite during the busy event schedule.

Take the Calm with You

FDB will offer booth visitors a complimentary "Chill Pill" pin and a Zen-inspired adult coloring book. Attendees may enter a raffle for a Theragun Mini 3rd Gen portable massage device by scanning their badge at the booth. Winners do not need to be present to win and will be notified on Wednesday afternoon.

Visit FDB at HIMSS26 at Booth #3235
Schedule a meeting with FDB at HIMSS26 here.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.


Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> FDB Emphasizes Medication Intelligence for AI and Clinical Workflows at HIMSS 2026
 
Next-generation medication intelligence and immersive booth experiences anchor FDB presence at the 2026 HIMSS Global Health Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 -- FDB (First Databank), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will bring its vision of "Intelligence to Free Your Mind" to the 2026 HIMSS Global Health Conference & Exhibition at the Venetian Convention & Expo Center in Las Vegas. At HIMSS26, FDB will highlight how its medication intelligence—built on decades of trusted drug knowledge and delivered in patient-specific clinical context—reduces cognitive burden, restores focus, and strengthens both human and AI-enabled workflows. Across solution demonstrations, interactive exhibit-floor experiences, and hosted events, the company will showcase how it is advancing medication intelligence embedded in clinical workflows to support clarity, confidence, and consistency at scale.

FDB will also engage health technology leaders at HIMSS26 in conversations about how validated, context-rich medication intelligence enhances AI performance, establishes analytics integrity, supports workflow automation, and reduces the burden of maintaining complex drug logic internally.

"As AI capabilities expand, analytics grow more sophisticated, and digital health solutions move closer to clinical decision-making, medication data alone is no longer sufficient," said Virginia Halsey, vice president of strategy and product management at FDB. "Advanced medication intelligence, powered by trusted, patient-specific drug knowledge, is now foundational to modern health technology platforms."

Through innovations including its Model Context Protocol (MCP), now called FDB MedProof MCP™, FDB is helping technology teams confidently connect agentic systems and applications to standardized, patient-specific medication intelligence—enabling scalable innovation while safeguarding accuracy and trust.

Step into Calm with Medication Intelligence to Free Your Mind

At booth #3235, FDB will invite HIMSS26 attendees to step into calm and experience what less noise and clearer focus look like in practice. Demonstrations will show how medication intelligence, applied consistently across prescribing, pharmacy verification, medication decision support, and patient education, can reduce unnecessary steps, minimize interruptions, and help clinicians think more clearly within the flow of care.

FDB will highlight solutions that many health systems already rely on as the foundation of safe medication use:

FDB MedKnowledge® delivers the clinically robust drug knowledge that serves as the foundation for FDB's medication intelligence across clinical workflows, giving clinicians certainty when it matters most. FDB Meducation and FDB Meducation Bedside also support safe medication use plus adherence to treatment regimens by enabling clinicians to more easily provide patients with clear, personalized medication instructions at discharge and at the bedside.

FDB AlertSpace® 2.0 introduces the next evolution of the trusted solution, helping healthcare organizations reduce generalized, non-actionable alerts that distract clinicians from patient care and contribute to alert fatigue. Building on the collaborative alert customization capabilities health systems rely on, the new version delivers a modern user experience and scalable architecture for faster adoption and continuous improvement. Embedded analytics and community insights enable teams to evaluate alert performance, acceptance rates, and peer benchmarks within the workflow, while a centralized workspace strengthens governance and change management. An integrated AI Copilot further accelerates time to value by providing access to trusted guidance directly within the platform.

HIMSS26 attendees can further explore the next generation of clinical decision support (CDS) through FDB PatientFirst™ solutions. For patient-specific precision, FDB Targeted Medication Warnings™ and FDB Pharmacogenomic CDS help ensure fewer interruptions and clearer decisions by delivering alerts that reflect each patient's unique clinical context.

On the operations side, FDB Vela™ demonstrates how a modern ePrescribing network can support connected, resilient medication workflows with no single point of failure, while empowering innovation in electronic prescribing.

Agentic & Automation Innovations Unveiled

As healthcare organizations look beyond optimizing individual workflows toward safely scaling AI and automation, FDB will showcase at HIMSS26 how it is building on its medication intelligence foundation with new infrastructure designed for governance, resilience, and long-term flexibility.

FDB will highlight FDB MedProof MCP, the first AI-native server solution that anchors healthcare agents in trusted, current, accountable medication intelligence for CDS. Serving as an agentic orchestration layer that increases speed to market and reduces ongoing maintenance, the MCP enables health tech leaders to standardize how medication intelligence is governed, accessed, and applied across scalable AI-enabled workflows

FDB will also preview its own purpose-built workflow automation innovations that apply medication intelligence to reduce manual effort while preserving clinical judgment. FDB Script Agent™, the company's new AI-empowered prescription automation agent, is designed for ambulatory care settings, where clinicians often spend significant time manually entering structured prescription orders after patient encounters. Available via MCP or API integration and anchored in validated FDB medication intelligence, Script Agent advances ambient listening to the next level by taking action. It uses spoken information captured during patient visits to auto-queue structured prescription orders directly into the electronic health record (EHR) for clinician review and approval.

In addition, FDB will preview FDB VerifyAssist™, a workflow assistant designed to reduce the burden of medication order verification, which can take 30% to 40% of a hospital pharmacist's time. FDB VerifyAssist automatically surfaces the most important drug-specific verification criteria against each patient's current clinical data (e.g., relevant lab results, age, and other factors) at the point of verification. This helps hospital pharmacists quickly identify orders that warrant closer review.

Another persistent, time-consuming challenge confronting clinicians is accurately reconciling a patient's medication list at every transition of care. Incomplete histories create risk. At HIMSS26, FDB will demonstrate how its EHR-integrated medication reconciliation solution, powered by trusted medication intelligence, supports safety checks and helps clinicians create and maintain accurate, consistent medication lists across the flow of care.

Together, these solutions illustrate how FDB is moving from point optimizations toward a system-level approach that lets intelligence carry more of the load across the end-to-end medication workflow.

Learn More in Daily FDB-Hosted Micro-Sessions

Throughout the conference, FDB experts will host short, focused micro-sessions at booth #3235. These sessions will help attendees discover how specific capabilities reduce manual effort, improve consistency, and ease cognitive load across medication-related workflows.

FDB's Agentic Innovations
How FDB powers agentic workflows with medication intelligence, featuring FDB Script Agent and MCP
Tuesday, March 10: 10:30 a.m. and 1:00 p.m.
Wednesday, March 11: 10:30 a.m. and 1:00 p.m.
Thursday, March 12: 10:30 a.m.

FDB's Medication Intelligence Innovations
When medication information is not clear upfront, reconciliation and verification turn into detective work, featuring FDB Medication Reconciliation and VerifyAssist
Tuesday, March 10: 11:30 a.m. and 2 p.m.
Wednesday March 11: 11:30 a.m. and 2 p.m.
Thursday, March 12: 11:30 a.m.

Attendees may inquire within the booth to schedule private sessions at a preferred time.

Calm Continues at Happy Hour

Extending its Intelligence to Free Your Mind theme, FDB will host "Calm Continues at Happy Hour" on Wednesday, March 11, from 4:00 to 5:30 p.m. at its exhibit booth. The reception offers attendees a space to pause, connect with peers, and continue meaningful conversations in a relaxed setting on the exhibit floor.

Guests will be served beer, wine, and soft drinks, along with curated cheese boards and macaron towers. Attendees will also receive a gift package of Greyston Bakery chocolate fudge brownies or chocolate chip blondies.

Recharge and Refresh through Restorative Booth Experiences

FDB invites HIMSS26 attendees to visit the FDB booth to experience restorative activities designed to embrace the spirit of calm. Complimentary foot and shoulder massage stations and infused water will be available to provide a brief respite during the busy event schedule.

Take the Calm with You

FDB will offer booth visitors a complimentary "Chill Pill" pin and a Zen-inspired adult coloring book. Attendees may enter a raffle for a Theragun Mini 3rd Gen portable massage device by scanning their badge at the booth. Winners do not need to be present to win and will be notified on Wednesday afternoon.

Visit FDB at HIMSS26 at Booth #3235
Schedule a meeting with FDB at HIMSS26 here.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.


Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> <![CDATA[DAVID DELANEY, MD, NAMED PRESIDENT OF DRUG KNOWLEDGE PROVIDER FDB]]> https://histalk.com/forum/showthread.php?tid=2263 Tue, 24 Feb 2026 16:04:26 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2263 DAVID DELANEY, MD, NAMED PRESIDENT OF DRUG KNOWLEDGE PROVIDER
FDB (FIRST DATABANK)
NEW YORK, February 24, 2026 — Hearst today named David Delaney, MD, president of its Hearst Health portfolio company FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions. The announcement was made by Hearst President and CEO Steven R. Swartz and Hearst Health President Gregory Dorn, MD. Delaney brings more than two decades of experience, including serving as a critical care physician and leading large-scale healthcare technology, clinical content, and decision support businesses across payer and provider markets.

Most recently, Delaney served as senior vice president and general manager of clinical decision support at Optum Insight, overseeing a broad portfolio of evidence-based content and software platforms supporting both payer and provider workflows. Before Optum, he held senior leadership roles at Change Healthcare and served as global vice president and chief medical officer for SAP Health.

“David’s appointment reflects Hearst Health’s long-term commitment to thoughtful growth and innovation,” said Dorn. “FDB is at an important moment, where trusted medication knowledge must evolve alongside AI-enabled care delivery. David’s leadership strengthens our ability to deliver validated, patient-specific medication intelligence that healthcare organizations can rely on as they innovate responsibly.”

Earlier in his career, Delaney practiced critical care medicine and led applied informatics initiatives at Beth Israel Deaconess Medical Center, where he gained firsthand experience with prescribing workflows, medication complexity, and the clinical impact of alert fatigue. He completed his medical training and fellowships at Harvard-affiliated hospitals and holds patents related to healthcare data and billing systems.

Delaney assumes the role of FDB president at a time when healthcare organizations are navigating rapid change driven by advances in AI, increasing medication complexity, and growing expectations for personalized, patient-specific care. Under his leadership, FDB will continue to build on its nearly 50-year foundation in medication safety while advancing clinically robust, workflow-integrated medication intelligence that supports modern healthcare delivery. As part of its support of modernization, FDB has launched the healthcare industry’s first Model Context Protocol (MCP) server for clinical decision support, providing a standardized, secure framework for integrating trusted medication knowledge directly into AI-driven and next-generation clinical applications.

“David brings a rare combination of clinical credibility, technology leadership, and operating experience at scale,” said Charles Tuchinda, MD, MBA, executive chairman of FDB and executive vice president, chief operating officer and deputy group head of Hearst Health. “His close connection to real-world clinical workflows and customer experiences positions FDB to deepen strategic collaborations across the healthcare ecosystem while reinforcing its role as a trusted medication knowledge solution.”

“FDB sits at a rare intersection of deep clinical expertise and trusted medication knowledge built over decades,” said Delaney. “Our focus is on extending that foundation with technology that adds intelligence without compromising rigor — delivering patient-specific, context-aware insights directly within clinical workflows. By executing on this while maintaining rigorous clinical validation, we will help clinicians make more confident medication decisions, reduce unnecessary burden, and preserve the trust that healthcare organizations place in FDB.”

Delaney will focus on advancing FDB’s platform strategy, deepening customer engagement, and responsibly applying AI to deliver more precise, patient-specific medication intelligence. David’s leadership reinforces FDB’s commitment to rigorous clinical validation, human oversight, and technology that scales trusted expertise across healthcare workflows.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB’s comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow FDB on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies – FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health – elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Hearst
Hearst is one of the nation’s largest global, diversified information, services and media companies. The company’s diverse portfolio includes global financial services leader Fitch Group; Hearst Health, a group of medical information and services businesses; Hearst Transportation, which includes CAMP Systems International, a major provider of software-as-a-service solutions for managing maintenance of jets and helicopters; ownership in cable television networks such as A&E, HISTORY, Lifetime and ESPN; 35 television stations; 30 daily and 50 weekly newspapers; digital services businesses; and more than 200 magazine editions around the world.

Media Contacts
Paul Luthringer, Hearst, 212-649-2540, Paul@Hearst.com]]> DAVID DELANEY, MD, NAMED PRESIDENT OF DRUG KNOWLEDGE PROVIDER
FDB (FIRST DATABANK)
NEW YORK, February 24, 2026 — Hearst today named David Delaney, MD, president of its Hearst Health portfolio company FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions. The announcement was made by Hearst President and CEO Steven R. Swartz and Hearst Health President Gregory Dorn, MD. Delaney brings more than two decades of experience, including serving as a critical care physician and leading large-scale healthcare technology, clinical content, and decision support businesses across payer and provider markets.

Most recently, Delaney served as senior vice president and general manager of clinical decision support at Optum Insight, overseeing a broad portfolio of evidence-based content and software platforms supporting both payer and provider workflows. Before Optum, he held senior leadership roles at Change Healthcare and served as global vice president and chief medical officer for SAP Health.

“David’s appointment reflects Hearst Health’s long-term commitment to thoughtful growth and innovation,” said Dorn. “FDB is at an important moment, where trusted medication knowledge must evolve alongside AI-enabled care delivery. David’s leadership strengthens our ability to deliver validated, patient-specific medication intelligence that healthcare organizations can rely on as they innovate responsibly.”

Earlier in his career, Delaney practiced critical care medicine and led applied informatics initiatives at Beth Israel Deaconess Medical Center, where he gained firsthand experience with prescribing workflows, medication complexity, and the clinical impact of alert fatigue. He completed his medical training and fellowships at Harvard-affiliated hospitals and holds patents related to healthcare data and billing systems.

Delaney assumes the role of FDB president at a time when healthcare organizations are navigating rapid change driven by advances in AI, increasing medication complexity, and growing expectations for personalized, patient-specific care. Under his leadership, FDB will continue to build on its nearly 50-year foundation in medication safety while advancing clinically robust, workflow-integrated medication intelligence that supports modern healthcare delivery. As part of its support of modernization, FDB has launched the healthcare industry’s first Model Context Protocol (MCP) server for clinical decision support, providing a standardized, secure framework for integrating trusted medication knowledge directly into AI-driven and next-generation clinical applications.

“David brings a rare combination of clinical credibility, technology leadership, and operating experience at scale,” said Charles Tuchinda, MD, MBA, executive chairman of FDB and executive vice president, chief operating officer and deputy group head of Hearst Health. “His close connection to real-world clinical workflows and customer experiences positions FDB to deepen strategic collaborations across the healthcare ecosystem while reinforcing its role as a trusted medication knowledge solution.”

“FDB sits at a rare intersection of deep clinical expertise and trusted medication knowledge built over decades,” said Delaney. “Our focus is on extending that foundation with technology that adds intelligence without compromising rigor — delivering patient-specific, context-aware insights directly within clinical workflows. By executing on this while maintaining rigorous clinical validation, we will help clinicians make more confident medication decisions, reduce unnecessary burden, and preserve the trust that healthcare organizations place in FDB.”

Delaney will focus on advancing FDB’s platform strategy, deepening customer engagement, and responsibly applying AI to deliver more precise, patient-specific medication intelligence. David’s leadership reinforces FDB’s commitment to rigorous clinical validation, human oversight, and technology that scales trusted expertise across healthcare workflows.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB’s comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow FDB on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies – FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health – elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Hearst
Hearst is one of the nation’s largest global, diversified information, services and media companies. The company’s diverse portfolio includes global financial services leader Fitch Group; Hearst Health, a group of medical information and services businesses; Hearst Transportation, which includes CAMP Systems International, a major provider of software-as-a-service solutions for managing maintenance of jets and helicopters; ownership in cable television networks such as A&E, HISTORY, Lifetime and ESPN; 35 television stations; 30 daily and 50 weekly newspapers; digital services businesses; and more than 200 magazine editions around the world.

Media Contacts
Paul Luthringer, Hearst, 212-649-2540, Paul@Hearst.com]]> <![CDATA[Altera Digital Health’s Sunrise Extends Partnerships with 14 Hospital Systems]]> https://histalk.com/forum/showthread.php?tid=2262 Tue, 24 Feb 2026 15:01:27 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2262 Altera Digital Health’s Sunrise Extends Partnerships with 14 Hospital Systems
Client momentum comes on the heels of major platform updates in Sunrise 25.1 and new product launches

NIAGARA FALLS, N.Y. - Altera Digital Health, a global health IT leader, today announced that 14 clients have renewed their contracts for the Sunrise™ electronic health record (EHR), reinforcing continued confidence in the platform’s direction, performance and value. The partnership renewals follow a year of significant platform advancement with the release of Sunrise 25.1, which added approximately 700 system enhancements, and the expansion of its product portfolio to support more connected and efficient clinical, financial and operational workflows across the enterprise.

Healthcare organizations that signed multi-year extensions with Sunrise include:

Made generally available in June 2025, Sunrise 25.1 was designed to simplify navigation, reduce cognitive burden and surface critical information at the point of care, reflecting a continued focus on usability and efficiency for clinical and operational teams alike. Additionally, Altera expanded the Sunrise ecosystem with the introduction of Sunrise Thread AI, a native ambient scribe and documentation assistant; Sunrise CarePath, a mobile patient engagement platform supporting secure messaging, self-scheduling, appointment reminders, notifications and online billing; and Sunrise Health Record, an intelligent faxing solution that embeds health information management (HIM) capabilities directly within the Sunrise EHR to streamline record management, improve compliance and reduce reliance on fragmented, third-party systems.

“Each renewed partnership is a testament to the confidence and trust in the direction of our product roadmap and the level of client service we strive for every day,” said Jay Adams, Executive Vice President for Sunrise, Altera Digital Health. “The enhancements we introduced over the last year are the direct result of really listening to our clients and understanding the challenges and opportunities before them. As healthcare continues to evolve, the Sunrise team stands ready to provide the solutions and guidance organizations need to adapt along with it.”

Learn more about Sunrise here.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Contacts
Media Contact
For Altera Digital Health
AlteraMediaRelations@alterahealth.com]]> Altera Digital Health’s Sunrise Extends Partnerships with 14 Hospital Systems
Client momentum comes on the heels of major platform updates in Sunrise 25.1 and new product launches

NIAGARA FALLS, N.Y. - Altera Digital Health, a global health IT leader, today announced that 14 clients have renewed their contracts for the Sunrise™ electronic health record (EHR), reinforcing continued confidence in the platform’s direction, performance and value. The partnership renewals follow a year of significant platform advancement with the release of Sunrise 25.1, which added approximately 700 system enhancements, and the expansion of its product portfolio to support more connected and efficient clinical, financial and operational workflows across the enterprise.

Healthcare organizations that signed multi-year extensions with Sunrise include:

Made generally available in June 2025, Sunrise 25.1 was designed to simplify navigation, reduce cognitive burden and surface critical information at the point of care, reflecting a continued focus on usability and efficiency for clinical and operational teams alike. Additionally, Altera expanded the Sunrise ecosystem with the introduction of Sunrise Thread AI, a native ambient scribe and documentation assistant; Sunrise CarePath, a mobile patient engagement platform supporting secure messaging, self-scheduling, appointment reminders, notifications and online billing; and Sunrise Health Record, an intelligent faxing solution that embeds health information management (HIM) capabilities directly within the Sunrise EHR to streamline record management, improve compliance and reduce reliance on fragmented, third-party systems.

“Each renewed partnership is a testament to the confidence and trust in the direction of our product roadmap and the level of client service we strive for every day,” said Jay Adams, Executive Vice President for Sunrise, Altera Digital Health. “The enhancements we introduced over the last year are the direct result of really listening to our clients and understanding the challenges and opportunities before them. As healthcare continues to evolve, the Sunrise team stands ready to provide the solutions and guidance organizations need to adapt along with it.”

Learn more about Sunrise here.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Contacts
Media Contact
For Altera Digital Health
AlteraMediaRelations@alterahealth.com]]> <![CDATA[Meet Bizmatics at the ViVE 2026 Conference!]]> https://histalk.com/forum/showthread.php?tid=2260 Thu, 19 Feb 2026 19:37:56 +0000 Jasmine Torres]]> https://histalk.com/forum/showthread.php?tid=2260 Bizmatics will be at the ViVE 2026 Conference - February 22–25, 2026, in Los Angeles, CA. We’ll be showcasing our EHR Software, PrognoCIS, along with our newest AI‑powered features designed for medical practices to streamline clinical workflows, reduce documentation time, and improve both patient and operational outcomes.

Stop by Booth #2305 to connect with us, ask questions, and see how PrognoCIS can support your practice.


[Image: ViVE.png]]]> Bizmatics will be at the ViVE 2026 Conference - February 22–25, 2026, in Los Angeles, CA. We’ll be showcasing our EHR Software, PrognoCIS, along with our newest AI‑powered features designed for medical practices to streamline clinical workflows, reduce documentation time, and improve both patient and operational outcomes.

Stop by Booth #2305 to connect with us, ask questions, and see how PrognoCIS can support your practice.


[Image: ViVE.png]]]> <![CDATA[Altera Digital Health Names Sean Sykes as Executive Vice President for Ventus]]> https://histalk.com/forum/showthread.php?tid=2259 Thu, 19 Feb 2026 15:14:37 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2259 Altera Digital Health Names Sean Sykes as Executive Vice President for Ventus
Veteran executive and sales leader to drive growth for healthcare revenue cycle and administration portfolio

NIAGARA FALLS, N.Y. — February 19, 2026 — Altera Digital Health, a global health IT leader, today announced that Sean Sykes has joined the company as Executive Vice President for Ventus, Altera’s suite of integrated revenue cycle and administrative solutions designed to optimize financial performance and operational efficiency. Sykes brings to the role more than 20 years of experience building and scaling high-performing sales and customer success teams at enterprise technology organizations.

Sykes comes to Altera following a successful tenure with multiple business units in the Harris Operating Group (Harris) of Constellation Software Inc., of which Altera is also a part. He most recently served as Senior Vice President for Sales and Customer Success at Advanced Utility Solutions, which provides customer information and billing software for municipal, investor-owned and cooperative utilities. Sykes also previously served as Vice President of Sales and Marketing for NorthStar, a software provider of customer experience solutions for modern utilities.

“I’m excited to join Altera Digital Health to support the organization’s growing footprint and expand the Ventus portfolio to meet new market demands as healthcare evolves,” said Sean Sykes, Executive Vice President for Ventus, Altera Digital Health. “I look forward to partnering with our clients to help them navigate shifting financial realities and continue refining their revenue cycle strategies.”

Prior to joining Harris, Sykes spent more than two decades in executive and sales leadership positions at several companies within the technology sector, including Peak Sales Recruiting, Avast, Bitheads and Carnegie Learning. Sykes earned his Bachelor of Arts at the University of Ottawa.

“From new payment models to AI advancements, care organizations need robust solutions and expert guidance to thrive in today’s complex healthcare environment and sustain long-term growth,” said Marcus Perez, President, Altera Digital Health. “I’m thrilled to welcome Sean to the team. His extensive enterprise technology experience and proven leadership within Harris will be invaluable assets to both our Ventus team and the clients we serve.”

Learn more about the Ventus portfolio of solutions here.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Media Contact
For Altera Digital Health
AlteraMediaRelations@alterahealth.com]]> Altera Digital Health Names Sean Sykes as Executive Vice President for Ventus
Veteran executive and sales leader to drive growth for healthcare revenue cycle and administration portfolio

NIAGARA FALLS, N.Y. — February 19, 2026 — Altera Digital Health, a global health IT leader, today announced that Sean Sykes has joined the company as Executive Vice President for Ventus, Altera’s suite of integrated revenue cycle and administrative solutions designed to optimize financial performance and operational efficiency. Sykes brings to the role more than 20 years of experience building and scaling high-performing sales and customer success teams at enterprise technology organizations.

Sykes comes to Altera following a successful tenure with multiple business units in the Harris Operating Group (Harris) of Constellation Software Inc., of which Altera is also a part. He most recently served as Senior Vice President for Sales and Customer Success at Advanced Utility Solutions, which provides customer information and billing software for municipal, investor-owned and cooperative utilities. Sykes also previously served as Vice President of Sales and Marketing for NorthStar, a software provider of customer experience solutions for modern utilities.

“I’m excited to join Altera Digital Health to support the organization’s growing footprint and expand the Ventus portfolio to meet new market demands as healthcare evolves,” said Sean Sykes, Executive Vice President for Ventus, Altera Digital Health. “I look forward to partnering with our clients to help them navigate shifting financial realities and continue refining their revenue cycle strategies.”

Prior to joining Harris, Sykes spent more than two decades in executive and sales leadership positions at several companies within the technology sector, including Peak Sales Recruiting, Avast, Bitheads and Carnegie Learning. Sykes earned his Bachelor of Arts at the University of Ottawa.

“From new payment models to AI advancements, care organizations need robust solutions and expert guidance to thrive in today’s complex healthcare environment and sustain long-term growth,” said Marcus Perez, President, Altera Digital Health. “I’m thrilled to welcome Sean to the team. His extensive enterprise technology experience and proven leadership within Harris will be invaluable assets to both our Ventus team and the clients we serve.”

Learn more about the Ventus portfolio of solutions here.

About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera’s approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we’re focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.

Media Contact
For Altera Digital Health
AlteraMediaRelations@alterahealth.com]]>